Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - cefalexin, quantity: 500 mg - capsule - excipient ingredients: microcrystalline cellulose; magnesium stearate - respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin max capsule is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin capsule in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and soft tissue infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis and klebsiella sp. the effectiveness of cephalexin max capsule in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin max capsule is not indicated in these conditions. note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin max capsule. renal function studies should be performed when indicated.

Kanada - Kiingereza - Health Canada

teva canada limited - cephalexin (cephalexin monohydrate) - capsule - 500mg - cephalexin (cephalexin monohydrate) 500mg - first generation cephalosporins

Kanada - Kiingereza - Health Canada

teva canada limited - cephalexin (cephalexin monohydrate) - tablet - 500mg - cephalexin (cephalexin monohydrate) 500mg - first generation cephalosporins

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin monohydrate -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin monohydrate -

Kanada - Kiingereza - Health Canada

pro doc limitee - cephalexin (cephalexin monohydrate) - tablet - 500mg - cephalexin (cephalexin monohydrate) 500mg - first generation cephalosporins

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 262.9mg equivalent to cephalexin 250 mg;   - capsule - 250 mg - active: cefalexin monohydrate 262.9mg equivalent to cephalexin 250 mg   excipient: gelatin   magnesium stearate microcrystalline cellulose titanium dioxide   water  

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefalexin monohydrate, quantity: 550 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; brilliant blue fcf; sunset yellow fcf; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections; strep. pneumoniae and group a b-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e.coli, p.mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin rbx is not indicated in these conditions. note. appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin rbx. renal function studies should be perfomed when indicated.

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - cefalexin - oral capsule - 500mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - cefalexin - oral capsule - 500mg